Flash flex video
You Asked. FlexTM Delivers.
Introducing a new generation of aorto-ostial excellence - engineered in response to physician feedback to enhance deliverability, safety and ease of use.
WHAT’S NEW
Enhanced Performance for Your
Most Demanding Cases
Only FLASH Flex™ achieves total aorto-ostial stent apposition
- Optimize Patient Outcomes
- Total & Efficient Lesion Coverage
- Streamlined Vessel Reaccess
confident outcomes
The FLASH System demonstrates consistently low restenosis at 6 months, below the 9% rate reported for accurate stent placement in ostial lesions.4*
More Solutions from Verge Medical
Now Introducing
Our Team
Adam Tschida
General Manager & COO
Brett Hersom
Vice President of Sales
Ted Karmon
Head of Commercial
Outpatient Solutions
Travis Winslow
Vice President of Quality
Jamey Jacobs
Medical Affairs
Sam Hesami
Corporate Controller &
Human Resources
newsroom
Verge Medical, a privately held medical technology company focused on advancing physician-driven solutions to address persistent gaps in vascular care, today announced the acquisition of the RoVo™ System and its patented Temporary Occlusion Embolectomy (TOE) technology from 2MG Medical. The acquisition enhances Verge’s expanding portfolio of targeted, setting-specific solutions for coronary and peripheral vascular interventions.
Ostial Corporation, a privately held medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, today announced the acquisition of the Wavella™ technology from Crossfire Medical. The company also unveiled its new identity as Verge Medical, marking a strategic expansion in the coronary and peripheral markets, with product offerings now in the inpatient and office-based settings.
Ostial Corporation (Ostial), a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, is pleased to announce the appointment of Mike Buck as its new Chief Executive Officer. Mike brings over 30 years of cardiovascular experience, having held several executive leadership positions at prominent companies, including Guidant, Abbott, Cardinal Health, and most recently, TRUVIC Medical.
Proceeds to accelerate commercialization and pipeline expansion of novel FLASH™ Aorto-Ostial Angioplasty System
Ostial Corporation (Ostial), a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, today announced the raise of $7.5M in growth funding led by Delos Capital with participation from AMED Ventures and other existing investors.
Ostial Corporation (Ostial), a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, today reached a new milestone, passing the mark of 15,000 commercial units sold of its FLASH™ Aorto-Ostial Angioplasty System (FLASH System) in over 300 hospitals across the United States. FLASH is the first and only dual balloon-based system designed for use in aorto-ostial angioplasty in coronary and peripheral cases.
Contact Us to Learn More
The RoVo™ Mechanical Thrombectomy Device is indicated for the removal of soft emboli and thrombi from vessels in the peripheral vasculature. The FLASH Flex™ system is a specialty balloon device and should only be used by physicians who are trained to use it. To request a complete copy of the IFU or user training, please contact customer service at [email protected].
* Compared to non-ostial lesions
- Data on file at Verge Medical
- Sanghvi K, Morris T, Kovach R. Optimal Aorto-ostial Lesion Treatment With Flash Ostial Balloon Is Feasible and Safe. JACC. 2016;9(4). Supplement S.
- Nguyen-Trong P, Martinez Parachini J, Resendes E, et al. Procedural Outcomes With Use of the Flash Ostial System in Aorto-Coronary Ostial Lesions. Catheter Cardiovasc Interv. 2016;88(7):1067-1074.
- Dishmon D, Elhaddi A, Packard K, et al. High Incidence of Inaccurate Stent Placement in the Treatment of Coronary Aorto-Ostial Disease. JIC. 2011;23(8).